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Erythrodermic psoriasis with regression after prophylaxis
with isoniazid and antidepressant therapy - Case report *
Psoríase eritrodérmica com regressão após profilaxia com isoniazida e terapia
antidepressiva - Relato de caso
Isabella Portela Redighieri1 Tatiana de Carvalho Maia1
Millena Accetta Nadal2 Tatiana Romeu Lorenzon Caliman2
Maria de Fátima Maklouf Amorim Ruiz3 Valeria Petri4
Abstract: An 83 year old woman, exhibiting severe psoriasis, was treated conventionally (phototherapy,
acitretin, and cyclosporine). After poor clinical results and significant changes in laboratory procedures,
those treatments were suspended. She was then being prepared to be submitted to biological treatment,
when preliminary results disclosed a 30mm PPD. Complete improvement occurred [only] after introduc-
ing prophylactic therapy for tuberculosis and anti-depressive medication.  
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Resumo: Mulher idosa apresentou psoríase em placas do tipo grave, com tendência eritrodérmica, e foi
submetida a tratamento de acordo com o algoritmo consensual (fototerapia, acitretina, ciclosporina).
Resultados clínicos insuficientes, recorrência e agravamento do quadro laboratorial orientaram no sentido
da introdução de terapia biológica. A avaliação preliminar revelou PPD de 30mm. A resolução completa das
lesões se verificou quando realizada profilaxia antituberculose e administrado antidepressivo. 
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CASE REPORT
INTRODUCTION
Psoriasis is a chronic immunologic disease, with
genetic background and inflammatory changes, which
affects the skin, the cutaneous appendages and the
joints. It afflicts approximately 2% of the world popu-
lation and it causes significant psychosocial damage. 1,2
Bacterial infections, medications and emotional stress
are among the triggering factors.  Patients resistant to
the classical treatment can be offered immune biolog-
ical treatment, which can lead to the control of the
process. 3-8 Tuberculosis is an infection that contraindi-
cates the use of immune biological drugs and chemo-
prophylaxis can work by eliminating the probable trig-
gering agent.
CASE REPORT
White female, 83 years old, original from Ururai
(SP), living in São Paulo, capital city, presented with
disseminated erythematous-desquamative lesions
(PASI = 7,2) for 18 months. The histopathological
examination was compatible with psoriasis. She
underwent phototherapy (PUVA and, afterwards, nar-
row band UVB, two sessions a week for 18 months),
without significant improvement.  She was then treat-
ed with acitretin (10mg/day), with marked improve-
ment of the disease but with significant alterations of
the hepatic enzymes. The drug was discontinued and
she was treated with topical emollients and pho-
totherapy (narrow band UVB). There was worsening
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of the clinical status and rise of the PASI to 14.6
(Figures 1 and 2). Besides, she had a PPD of 16 mm,
which prompted a pneumologic evaluation that did
not disclose active tuberculosis. Eight months after
the laboratory tests normalized treatment with
cyclosporine (200mg/day) started and after five
months there was an improvement of the PASI (4.8).
Recurrence developed slowly with the gradual reduc-
tion of the cyclosporine (50mg/week), and the initial
dose was reintroduced. The dermatosis was under
control for ten months when there was an alteration
of the renal function. Biological treatment was indi-
cated and the preconised screening tests revealed a
PPD test of 30mm. 
Active tuberculosis was excluded and prophy-
laxis with isoniazid, 300mg/day for six months began.
1 Simultaneously the patient´s depressive status was
treated with sertraline (50mg/day). After 90 days of
treatment there was a complete regression of the dis-
ease (Figures 3 and 4), without recurrence over the
subsequent months. 
DISCUSSION
Psoriasis is a common disease, with a world
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prevalence of around 2 to 3% and genetic predisposi-
tion, ambient aspects (traumas, lifestyle habits, and
medications), infections and psychological stress are
implicated on the development of the disease. 9, 10,11
Treatment is individualized and should be based on
the clinical presentation and severity of each case.
Elimination of probable causative agents is essential
and preliminary when planning the therapeutic
options. Because of resistance and intolerance to con-
ventional therapy of psoriasis, the immune biological
drugs area an option capable of promoting the con-
trol of the disease, the social reinsertion and an
improvement on the quality of life of the patients. 12
Tumor necrosis factor-alpha (TNF-alpha) has a central
role on the physiopathology of cutaneous and arthro-
pathic psoriasis and, at the same time, it is able to pre-
vent primary infection of tuberculosis, avoid its reacti-
vation and keep the causal agent latent. 13-17 There is
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sufficient evidence that inhibitors of TNF-alpha are
related to increased numbers of active tuberculosis.
18,19 The possibility of reactivation of latent tuberculo-
sis and rigorous screening on endemic areas should
be considered. 19-24 Besides, tuberculinic turning is
observed with treatment with cyclosporine, a drug
capable of suppressing immunity and facilitating the
reactivation of latent foci or even primary infection. 22
On the present case the previous treatment
with cyclosporine might have been responsible for the
relative immunosupression capable of reactivating a
latent focus or facilitating the development of primary
tuberculosis infection. The control of the latent infec-
tious process with chemoprophylaxis thus resulted in
an improvement of the severe psoriasis, and the con-
trol of the depressive status with medication might
have had an additional impact. ❑
